MYC and primary cutaneous T-cell non-Hodgkin lymphoma: Taking advantage of the recent discovery that inhibition of cMyc leads to drug resistance in melanoma and myeloma [12]–[14], we aimed to investigate whether cMyc is also involved in the regulation of the resistance to bortezomib in CTCL.